止咳药市场－全球产业规模、份额、趋势、机会、预测：按药物类别、给药途径、年龄层、最终用户、地区和竞争格局划分，2021-2031年

全球止咳药市场预计将从 2025 年的 16.7 亿美元成长到 2031 年的 22.6 亿美元，复合年增长率为 5.17%。

这些药物专门用于抑制咳嗽反射，其作用机制包括作用于中枢神经系统的咳嗽中枢或靶向周围神经系统，因此是治疗方法干咳、无痰咳嗽的主要药物。市场成长的主要驱动因素是全球老化人口中慢性呼吸系统疾病盛行率的上升，以及急性呼吸道感染疾病发生率的增加。此外，快速的都市化及其导致的日益严重的环境污染也加剧了呼吸系统疾病的发生，从而维持了对有效止咳药物的强劲需求。

儘管成长前景强劲，但由于阿片类药物製剂本身存在滥用和误用的风险，市场面临日益严格的监管审查，因此也面临巨大的挑战。欧洲自我护理产业协会 (AESCIA) 发布的《2025 年报告》指出，届时将有 47 亿剂用于治疗咳嗽、感冒等轻微健康问题的非处方药流通，这凸显了消费者对这些产品的高度依赖。然而，各地实施更严格的监管措施，以及某些止咳成分被重新归类为处方笺药，可能会阻碍产品的供应，并限制整体市场扩张。

市场驱动因素

慢性及急性呼吸系统疾病的日益普遍是全球止咳药市场的主要驱动力。病毒感染的周期性爆发和持续的感染疾病负担推动了这一增长，进而直接产生了对止咳治疗的需求。止咳药的需求显着增加，尤其是在流感季，咳嗽管理变得特别迫切。例如，美国疾病管制与预防中心 (CDC) 于 2025 年 5 月发布的关于 2024-2025 年流感季暂定负担的报告估计，美国流感病例数将在 4,700 万至 8,200 万之间，这意味着庞大的患者群体需要缓解症状。此外，慢性疾病也保证了季节性高峰以外的持续市场需求。正如世界卫生组织 (WHO) 于 2025 年 11 月发布的《2025 年全球结核病报告》所示，2024 年约有 1,070 万人将患有结核病，需要持续的症状管理。

同时，消费者对非处方止咳药的需求不断增长，以及自我治疗方式的普及，正显着推动市场收入的成长。消费者越来越重视非处方笺糖浆和润喉糖在缓解轻微呼吸道疾病方面的经济性和便利性，而较少寻求医疗协助。这种消费行为正在提升大型製药公司医疗保健部门的表现。例如，宝洁公司在2025年8月发布的《2025年年度报告》中指出，由于消费者持续依赖值得信赖的自我护理产品，其个人健康照护部门（包括其领先的呼吸系统品牌）实现了中等个位数的有机销售成长。这一趋势在新兴经济体尤为明显，这些地区不断扩张的零售网路使患者能够轻鬆获得止咳药，非处方产品正成为全球市场的基石。

市场挑战

对止咳药处方的严格监管严重阻碍了市场成长。世界各国政府都在实施严格的监管措施，以降低鸦片类药物和其他强效止咳药带来的成瘾和滥用风险。这些日益严格的监管措施往往将有效的非处方药重新归类为处方笺药，严重限制了公众取得这些药物的途径。此类监管措施为消费者的购买过程带来了许多不便，迫使患者选择就医并承担相关费用，而非便捷的自我护理方案，直接降低了生产商的销售量。

这些限制性政策背后的主要驱动力是滥用案例的不断发生，凸显了严格市场监管的必要性。根据消费者保健产品协会（CHPA）2025年的数据，高中二年级学生非医疗用途使用咳嗽和感冒药的比例将达到5.1%，这凸显了产品被挪作娱乐用途这一长期存在的问题。这项统计数据强化了监管机构维持高进入门槛的决心，导致製造商面临通路和收入成长受阻的困境。严格的合规环境阻碍了这些必需治疗方法的商业性扩充性。

市场趋势

P2X3受体拮抗剂在慢性咳嗽治疗领域的商业化正蓬勃发展，有望解决难治性疾病患者亟待解决的重大医疗需求。与传统的中枢性鸦片类药物不同，这些创新药物针对週边受体，抑制高敏性咳嗽反射，且不会引起镇静或依赖性。这为对标准治疗无效的患者提供了必要的替代方案。在成功完成后期临床试验后，这种标靶治疗方法即将上市。尤其值得一提的是，FirstWord Pharma于2025年3月发表的报导「Trevi菌株在难治性慢性咳嗽治疗中备受期待」的文章，重点介绍了这类新兴药物的潜在疗效。文章指出，在IIb期SOOTHE试验中，P2X3拮抗剂camlipixant与安慰剂相比，可使24小时咳嗽频率降低34%。

同时，人工智慧驱动的诊断与数位化咳嗽监测的融合正在革新评估方法，使其从主观的患者报告转向客观的数据量化。先进的演算法正被用于透过穿戴式技术被动地追踪咳嗽模式和频率，从而为临床试验和远端患者监护提供检验的终点指标。这项技术进步解决了呼吸系统研究中长期以来患者自我报告数据不可靠的难题。例如，Hyfe公司于2024年10月发布的一份题为《自动化人工智慧驱动的Hyfe连续咳嗽监测系统的检验与准确性》的报告证实，该公司的人工智慧系统在546小时的连续监测中，对咳嗽事件的检测灵敏度达到了90.4%，证明了数位生物标誌物在真实临床环境中的可靠性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球止咳药市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物分类（週边促效剂、中枢促效剂、其他）
  • 给药途径（吸入、口服、其他）
  • 依年龄组别（老年人、儿童、成人）
  • 依最终使用者（居家医疗、医院/专科诊所、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美止咳药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲止咳药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区止咳药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲止咳药市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲止咳药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球止咳药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Ltd.
• Bayer AG
• Ipca Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Hikma Pharmaceuticals PLC
• Unique Pharmaceuticals Limited
• Cipla Inc.
• Viatris Inc.
• Aurobindo Pharma

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Antitussive Drugs Market is projected to expand from USD 1.67 Billion in 2025 to USD 2.26 Billion by 2031, registering a CAGR of 5.17%. These pharmaceutical agents are specifically formulated to inhibit the coughing reflex, serving as a primary treatment for dry, non-productive coughs by acting on the cough center in the central nervous system or targeting the peripheral nervous system. Market growth is largely fueled by the increasing frequency of acute respiratory tract infections alongside a higher prevalence of chronic respiratory disorders within an aging global demographic. Furthermore, rapid urbanization and the consequent escalation in environmental pollution are leading to more frequent respiratory ailments, thereby maintaining strong demand for effective cough suppression solutions.

Despite these positive growth prospects, the market confronts substantial challenges stemming from regulatory scrutiny over opioid-based formulations, given the inherent risks of abuse and misuse. Highlighting the heavy consumer dependence on these products, the Association of the European Self-Care Industry reported in 2025 that the sector distributed 4.7 billion packs of non-prescription medicines for managing minor health issues, including cough and cold. However, the implementation of stricter regulations and the reclassification of specific antitussive ingredients to prescription-only status in various regions threaten to hinder product accessibility and constrain overall market expansion.

Market Driver

The escalating prevalence of both chronic and acute respiratory disorders serves as a primary engine for the Global Antitussive Drugs Market. This growth is driven by the cyclical nature of viral outbreaks and the enduring burden of infectious diseases, which create a direct need for cough suppression therapies. Demand for antitussives notably surges during severe influenza seasons when cough management becomes urgent; for example, the Centers for Disease Control and Prevention's May 2025 report on the preliminary burden of the 2024-2025 flu season estimated between 47 million and 82 million influenza illnesses in the United States, representing a vast patient population seeking symptomatic relief. Additionally, chronic conditions ensure sustained market demand beyond seasonal spikes, as evidenced by the World Health Organization's 'Global Tuberculosis Report 2025' from November 2025, which noted that approximately 10.7 million individuals fell ill with tuberculosis in 2024, necessitating ongoing symptom management.

Concurrently, the increasing demand for Over-the-Counter (OTC) antitussive medications and the rise of self-medication practices are significantly boosting market revenue. Consumers are frequently opting to skip primary care visits for minor respiratory issues in favor of the affordability and convenience offered by non-prescription syrups and lozenges. This consumer behavior is strengthening the financial results of major pharmaceutical health divisions; for instance, Procter & Gamble's '2025 Annual Report' from August 2025 highlighted that their Personal Health Care segment, which includes key respiratory brands, attained mid-single-digit organic sales growth due to continued reliance on trusted self-care products. This trend is especially pronounced in emerging economies, where broader retail access allows patients to readily obtain cough remedies, establishing OTC products as a fundamental pillar of the global market.

Market Challenge

Intense regulatory scrutiny regarding antitussive formulations presents a significant barrier to market growth. Governments worldwide are enforcing strict controls to curb the risks of dependence and abuse linked to opioid-based and other potent cough suppressants. This tightening often leads to the reclassification of effective over-the-counter medications to prescription-only status, which sharply limits their availability to the general public. Such regulatory actions create considerable friction in the consumer purchasing journey, forcing patients to dedicate time and money toward physician consultations instead of accessing convenient self-care solutions, which directly reduces sales volumes for manufacturers.

The ongoing occurrence of misuse incidents acts as the main driver for these restrictive policies, validating the need for stringent market oversight. Data from the Consumer Healthcare Products Association in 2025 indicated that the prevalence rate for nonmedical use of cough and cold medications among 10th graders reached 5.1%, underscoring the persistent problem of product diversion for recreational use. This statistic reinforces the resolve of regulators to uphold high access barriers, subsequently causing manufacturers to struggle with limited distribution channels and suppressed revenue growth as the rigorous compliance environment hampers the commercial scalability of these vital therapies.

Market Trends

The commercialization of P2X3 receptor antagonists for chronic cough is gaining momentum as a means to address the critical unmet needs of patients suffering from refractory conditions. In contrast to traditional centrally acting opioids, these innovative agents target peripheral receptors to suppress the hypersensitized cough reflex without inducing sedation or dependence, providing a necessary alternative for individuals who do not respond to standard treatments. This targeted therapeutic approach is nearing market readiness following successful late-stage clinical validation; notably, a March 2025 article by FirstWord Pharma titled 'Trevi soars on hopes for refractory chronic cough treatment' reported that the P2X3 antagonist camlipixant achieved a 34% placebo-adjusted reduction in 24-hour cough frequency during the Phase IIb SOOTHE trial, highlighting the potential efficacy of this emerging drug class.

In parallel, the integration of AI-driven diagnostics and digital cough monitoring is revolutionizing assessment methods by shifting from subjective patient reports to objective data quantification. Advanced algorithms are increasingly being utilized to passively track cough patterns and frequency through wearable technology, offering verifiable endpoints for clinical trials and remote patient monitoring. This technological advancement addresses the historic unreliability of self-reported data in respiratory research. For example, a report by Hyfe in October 2024, titled 'Validation and Accuracy of the Automated AI-powered Continuous Hyfe Cough Monitoring System,' confirmed that their AI system demonstrated a 90.4% sensitivity in detecting cough events over 546 hours of continuous monitoring, proving the reliability of digital biomarkers in real-world settings.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Ltd.
• Bayer AG
• Ipca Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Hikma Pharmaceuticals PLC
• Unique Pharmaceuticals Limited
• Cipla Inc.
• Viatris Inc.
• Aurobindo Pharma

Report Scope

In this report, the Global Antitussive Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antitussive Drugs Market, By Drug Class

• Peripherally Acting Drugs
• Centrally Acting Drugs
• Others

Antitussive Drugs Market, By Route of Administration

• Inhalational
• Oral
• Others

Antitussive Drugs Market, By Age Group

• Geriatric
• Pediatric
• Adult

Antitussive Drugs Market, By End-User

• Homecare
• Hospitals & Specialty Clinics
• Others

Antitussive Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antitussive Drugs Market.

Available Customizations:

Global Antitussive Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antitussive Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others)
  • 5.2.2. By Route of Administration (Inhalational, Oral, Others)
  • 5.2.3. By Age Group (Geriatric, Pediatric, Adult)
  • 5.2.4. By End-User (Homecare, Hospitals & Specialty Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Antitussive Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Age Group
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antitussive Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Age Group
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Antitussive Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Age Group
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Antitussive Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Age Group
      • 6.3.3.2.4. By End-User

7. Europe Antitussive Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Age Group
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antitussive Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Age Group
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Antitussive Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Age Group
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Antitussive Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Age Group
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Antitussive Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Age Group
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Antitussive Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Age Group
      • 7.3.5.2.4. By End-User

8. Asia Pacific Antitussive Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Age Group
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antitussive Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Age Group
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Antitussive Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Age Group
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Antitussive Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Age Group
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Antitussive Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Age Group
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Antitussive Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Age Group
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Antitussive Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Age Group
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antitussive Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Age Group
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Antitussive Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Age Group
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Antitussive Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Age Group
      • 9.3.3.2.4. By End-User

10. South America Antitussive Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Age Group
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antitussive Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Age Group
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Antitussive Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Age Group
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Antitussive Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Age Group
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antitussive Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Intas Pharmaceuticals Ltd.
• 15.3. Bayer AG
• 15.4. Ipca Laboratories Ltd.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Hikma Pharmaceuticals PLC
• 15.7. Unique Pharmaceuticals Limited
• 15.8. Cipla Inc.
• 15.9. Viatris Inc.
• 15.10. Aurobindo Pharma

16. Strategic Recommendations

17. About Us & Disclaimer